AstraZeneca Sues Watson Over Generic Pulmicort

Law360, New York (June 27, 2011, 7:27 PM EDT) -- AstraZeneca PLC filed a patent infringement suit against Watson Laboratories Inc. on Thursday in New Jersey, aiming to stop it from selling a generic form of asthma drug Pulmicort Respules.

Watson is the latest generic maker to file an abbreviated new drug application with the U.S. Food and Drug Administration to market generic Pulmicort, and London-based AstraZeneca says the proposed generic infringes two of its patents for the drug that are not due to expire until 2018.

Pulmicort, known generically as budesonide inhalation suspension, is a...
To view the full article, register now.